BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35655319)

  • 1. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).
    Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Adame-Garcia SR; Arang N; Lubrano S; De Francesco EM; Belfiore A; Gutkind JS; Maggiolini M
    J Exp Clin Cancer Res; 2022 Jun; 41(1):193. PubMed ID: 35655319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
    Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
    Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
    Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
    Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
    J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.
    Begg LR; Orriols AM; Zannikou M; Yeh C; Vadlamani P; Kanojia D; Bolin R; Dunne SF; Balakrishnan S; Camarda R; Roth D; Zielinski-Mozny NA; Yau C; Vassilopoulos A; Huang TH; Kim KA; Horiuchi D
    Commun Med (Lond); 2024 Feb; 4(1):22. PubMed ID: 38378783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway.
    Xu J; Fang X; Long L; Wang S; Qian S; Lyu J
    Cancer Biol Ther; 2021 Jan; 22(1):5-11. PubMed ID: 33307962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP transduction drives triple-negative breast cancer aggressiveness through modulating the EGFR‒AKT axis in patient-derived xenograft cells.
    Parambil ST; Thankayyan SKR; Antony GR; Littleflower AB; Augustine P; Somanathan T; Subhadradevi L
    Med Oncol; 2023 Apr; 40(5):137. PubMed ID: 37014473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
    Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
    Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF181 modulates Hippo signaling and triple negative breast cancer progression.
    Zhou R; Ding Y; Xue M; Xiong B; Zhuang T
    Cancer Cell Int; 2020; 20():291. PubMed ID: 32655323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
    Yin C; Li H; Zhang B; Liu Y; Lu G; Lu S; Sun L; Qi Y; Li X; Chen W
    Breast Cancer Res Treat; 2013 Nov; 142(2):297-309. PubMed ID: 24177755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.
    Li Z; Su P; Ding Y; Gao H; Yang H; Li X; Yang X; Xia Y; Zhang C; Fu M; Wang D; Zhang Y; Zhuo S; Zhu J; Zhuang T
    Cell Commun Signal; 2022 Oct; 20(1):164. PubMed ID: 36280829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition.
    Begg LR; Orriols AM; Zannikou M; Yeh C; Vadlamani P; Kanojia D; Bolin R; Dunne SF; Balakrishnan S; Camarda R; Roth D; Zielinski-Mozny NA; Yau C; Vassilopoulos A; Huang TH; Kim KA; Horiuchi D
    bioRxiv; 2023 Sep; ():. PubMed ID: 37790346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling.
    Volz HC; Laohachewin D; Seidel C; Lasitschka F; Keilbach K; Wienbrandt AR; Andrassy J; Bierhaus A; Kaya Z; Katus HA; Andrassy M
    Basic Res Cardiol; 2012 Mar; 107(2):250. PubMed ID: 22318783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A8/A9 is associated with estrogen receptor loss in breast cancer.
    Bao YI; Wang A; Mo J
    Oncol Lett; 2016 Mar; 11(3):1936-1942. PubMed ID: 26998104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.
    Ghavami S; Rashedi I; Dattilo BM; Eshraghi M; Chazin WJ; Hashemi M; Wesselborg S; Kerkhoff C; Los M
    J Leukoc Biol; 2008 Jun; 83(6):1484-92. PubMed ID: 18339893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.
    Talia M; Cirillo F; Spinelli A; Zicarelli A; Scordamaglia D; Muglia L; De Rosis S; Rigiracciolo DC; Filippelli G; Perrotta ID; Davoli M; De Rosa R; Macirella R; Brunelli E; Miglietta AM; Nardo B; Tosoni D; Pece S; De Francesco EM; Belfiore A; Maggiolini M; Lappano R
    J Exp Clin Cancer Res; 2023 Jul; 42(1):164. PubMed ID: 37434266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
    Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
    Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.